MILFORD, MA — Nitto Avecia Inc. (Avecia) announced today the successful completion of the first synthesis
runs at the 1.6 Mol scale which is believed to be the largest synthesis scale ever executed for oligonucleotide
API (active pharmaceutical ingredients) at its new oligonucleotide manufacturing facility in Milford, MA. This
exciting news comes only months after bringing into operation Avecia’s new API manufacturing synthesis
capabilities. This manufacturing capacity expansion increases Avecia’s total synthesis capacity to more than 3
Mol. Nitto Avecia’s President Detlef Rethage stated: “Avecia’s leadership in the oligonucleotide market is
significant and we are proud to have added this major manufacturing scale in less than two years to address a
capacity shortage that could have slowed down our client’s clinical trial progress. With our 1.6 Mol synthesis
capabilities now operational, the capacity shortage in oligonucleotides manufacturing has now been
addressed.”

ABOUT NITTO AVECIA INC.
Nitto Avecia Inc. is a recognized leader in manufacturing and development services of oligonucleotide
therapeutic with facilities located in Milford, MA.; Marlboro, MA.; and Cincinnati OH offering services for
DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg
+ post commercial launch. More information: www.Avecia.com. Nitto Avecia is proud member of Nitto
Group. More information: www.Nitto.com